Cargando…
Phosphodiesterase 4 inhibitor apremilast improves insulin resistance in psoriasis patients
Autores principales: | Ikumi, Kyoko, Torii, Kan, Sagawa, Yoko, Kanayama, Yoshifumi, Nakada, Aya, Nishihara, Haruna, Morita, Akimichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304264/ https://www.ncbi.nlm.nih.gov/pubmed/34961971 http://dx.doi.org/10.1111/1346-8138.16286 |
Ejemplares similares
-
Efficacy and safety of apremilast and phototherapy versus phototherapy only in psoriasis vulgaris
por: Morita, Akimichi, et al.
Publicado: (2022) -
Bath Psoralen Plus UVA Therapy Suppresses Keratinocyte-Derived Chemokines in Pathogenetically Relevant Cells
por: Kanayama, Yoshifumi, et al.
Publicado: (2021) -
Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast
por: Gooderham, Melinda, et al.
Publicado: (2015) -
Comparison of the Efficacy and Safety of Bexarotene and Photo(Chemo)Therapy Combination Therapy and Bexarotene Monotherapy for Cutaneous T-Cell Lymphoma
por: Morita, Akimichi, et al.
Publicado: (2022) -
A case of mycosis fungoides effectively treated with ultraviolet light A 1‐light‐emitting diode phototherapy
por: Ikumi, Kyoko, et al.
Publicado: (2022)